Business
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel
BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Gary H. Loeb as
About this update from Sangamo Therapeutics, Inc.
[{"type":"text","content":" BRISBANE, Calif.--(BUSINESS WIRE)--\nSangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Gary H. Loeb as Executive Vice President and General Counsel, effective immediately. Mr. Loeb will oversee all legal matters for Sangamo and will report to the Chief Executive Officer.\n\n\n“Gary brings dynamic experience in pharmaceutical compliance, legal operations, and executive leadership,” said Sandy Macrae, Sangamo's Chief Executive Officer. “We are pleased Gary is joining Sangamo and look forward to his contributions as Sangamo continues to grow as a clinical stage development company, and eventually into commercialization.”\n\n\nMr. Loeb has over 20 years of experience in biotechnology and pharmaceutical law, compliance, intellectual property, litigation, human resources, regulatory, and facilities. Before joining Sangamo, he served as General Counsel, Corporate Secretary, and Chief Compliance Officer at Achaogen, an anti-infectives company. At Achaogen, Mr. Loeb was a member of the Executive Team and the first full-time in-house attorney, where he built the legal and compliance teams. Before Achaogen, Mr. Loeb worked in roles of increasing responsibility at Counsyl, a genetic screening company, Amyris, Inc., and Genentech.\n\n\nMr. Loeb received his B.S. and B.A. degrees from Stanford University and his J.D. from Columbia Law School.\n\n\nAbout Sangamo Therapeutics \n\n\nSangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com\n\n\nForward-Looking Statements \n\n\nThis press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, references to Sangamo's anticipated growth as a clinical stage development company and into commercialization. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to: the costly and inherently uncertain rese...